Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components
- 112 Downloads
Diabetic macular edema (DME) is still one of the main causes of visual impairment. Repeated intravitreal injections of ranibizumab are considered the gold standard treatment, but the efficacy in patients with prominent cystic characteristics remains uncertain. In diabetic retinas, the identification of both antero-posterior and, particularly, tangential tractions is crucial to prevent misdiagnosis of tractional and refractory DME, and therefore to prevent poor treatment outcomes. The treatment of tractional DME with anti-VEGF injections could be poorly effective due to the influence of a tractional force. Pars plana vitrectomy (PPV) is a surgical procedure that has been widely used in the treatment of diffuse and refractory DME. Anatomical improvement, although stable and immediate, did not result in visual improvement. PPV with internal limiting membrane (ILM) peeling for the treatment of non-tractional DME in patients with prominent cysts (> 390 μm) causes subfoveal atrophy, defined as “floor effect”. Epiretinal tangential forces and intraretinal change evaluation by SD-OCT of non-tractional DME are essential for determining appropriate management.
KeywordsDiabetic macular edema Non-tractional macular edema Diabetic retinopathy
The authors have no proprietary interest in any aspect of this study.
MRR, DA, MF, CDG, SS contributed to conception and design; MRR, DA, IB, GC to acquisition of data, all authors contributed to interpretation of data; all authors drafted the article and approved its final version.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare that they have conflict of interest.
- 4.Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870. https://doi.org/10.1097/01.iae.0000242842.14624.e7 CrossRefGoogle Scholar
- 7.Diabetic Retinopathy Clinical Research Network MJ, Elman MJ, Qin H, et al (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119:2312–2318. https://doi.org/10.1016/j.ophtha.2012.08.022 CrossRefGoogle Scholar
- 12.Browning DJ (2010) Interpreting thickness changes in the diabetic macula: the problem of short-term variation in optical coherence tomography-measured macular thickening (an american ophthalmological society thesis). Trans Am Ophthalmol Soc 108:62–76Google Scholar
- 19.Gella L, Raman R, Kulothungan V, Sharma T (2012) Prevalence of posterior vitreous detachment in the population with type II diabetes mellitus and its effect on diabetic retinopathy: Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetic study SN-DREAMS report no. 23. Jpn J Ophthalmol 56:262–267. https://doi.org/10.1007/s10384-012-0134-7 CrossRefGoogle Scholar
- 23.Sebag J, Gupta P, Rosen RR et al (2007) Macular holes and macular pucker: the role of vitreoschisis as imaged by optical coherence tomography/scanning laser ophthalmoscopy. Trans Am Ophthalmol Soc 105:121–129 discusion 129–31Google Scholar
- 37.Zhang Z-H, Liu H-Y, Hernandez-Da Mota SE et al (2013) Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol 156:106–115.e2. https://doi.org/10.1016/j.ajo.2013.02.008 CrossRefGoogle Scholar
- 41.Van Geest RJ, Lesnik-Oberstein SY, Tan HS et al (2012) A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 96:587–590. https://doi.org/10.1136/bjophthalmol-2011-301005 CrossRefGoogle Scholar
- 55.Romano MR, Ilardi G, Ferrara M et al (2018) Intraretinal changes in idiopathic versus diabetic epiretinal membranes after macular peeling. PLoS One 13. https://doi.org/10.1371/journal.pone.0197065
- 62.Silva KC, Rosales MAB, Biswas SK et al (2009) Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 58:1382–1390. https://doi.org/10.2337/db09-0166 CrossRefGoogle Scholar